Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 2/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863991 | 1.00 | GLO1 (0.47) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL29350792 | 0.98 | GLO1 (0.48) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL22111148 | 0.94 | GLO1 (0.49) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL32670748 | 0.94 | GLO1 (0.49) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL6863995 | 0.92 | GLO1 (0.45) | GLO1PTGS1GSTK1BMP1ALDH1A1 | |
| SCHEMBL29050824 | 0.91 | PTGS1 (0.51) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL2804509 | 0.91 | PTGS1 (0.51) | GLO1PTGS1GSTK1FOLH1RIMKLA | |
| SCHEMBL30631707 | 0.88 | PTGS1 (0.43) | GLO1PTGS1GSTK1ALDH1A1LMNA | |
| SCHEMBL22892433 | 0.87 | GLO1 (0.43) | GLO1PTGS1GSTK1ALDH1A1LMNA | |
| SCHEMBL30261857 | 0.87 | FOLH1 (0.47) | GLO1FOLH1RIMKLANAALAD2BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228958-A1 | TSP1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-17 | — | — | US | claimed |
| EP-4467561-A1 | TSP1 INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2024-11-27 | — | — | EP | claimed |
| WO-2023136342-A1 | TSP1 INHIBITOR | 第一三共株式会社 | 2023-07-20 | — | — | WO | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12514939-B2 | Stable radiopharmaceutical compositions and uses thereof | ALPHA-9 ONCOLOGY, INC. (CA) | 2026-01-06 | — | — | US | disclosed |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ALPHA-9 ONCOLOGY INC. (CA) | 2025-08-14 | — | — | US | disclosed |
| US-20250228958-A1 | TSP1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4467561-A1 | TSP1 INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023136342-A1 | TSP1 INHIBITOR | 第一三共株式会社 | 2023-07-20 | — | — | WO | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-6799121-B2 | AUTOMATIC PROCESS | YORK UNIVERSITY (CA) | 2004-09-28 | — | — | US | disclosed |
| US-20020001814-A1 | Sequencing of peptides by mass spectrometry | YORK UNIVERSITY | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | GLO1 102/4885PTGS1 2882/4885GSTK1 2251/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | GLO1 1188/4885PTGS1 3440/4885GSTK1 1642/4885 |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RCN1, RABL6, QPCT | GLO1 801/4885PTGS1 4381/4885GSTK1 1887/4885 |
| US-20250228958-A1 | TSP1 INHIBITOR | ANXA11, SERPINC1, NPR1 | GLO1 3966/4885PTGS1 1185/4885GSTK1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.